Lenvatinib versus ramucirumab after first-line immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (SELECT-400, JON2101-H): a randomised non-inferiority phase 3 study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #331P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Checkpoint inhibition • Clinical • Head-to-Head • Metastases • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor • AFP
|
|
Hidetaka Tsumura; Satoshi Kobayashi; Atsushi Miyamoto; Akinori Asagi; Naohiro Okano; Gou Murohisa; Katsutoshi Sugimoto; Naoya Kanogawa; Hiroaki Nagano; Michitaka Imai; Takeshi Okamoto; Taro Yamashita; Shinya Endo; Yuta Maruki; Toshihiro Misumi; Makoto Ueno; Junji Furuse
|